Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial

We present the interim results of the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac. This was a randomized, observer-blinded, non-inferiority trial (NCT04942405). Volunteers were 18–55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanriover, Mine Durusu, Aydin, Ozlem Altuntas, Guner, Rahmet, Yildiz, Orhan, Celik, Ilhami, Doganay, Hamdi Levent, Kose, Sukran, Akhan, Sila, Akalin, Emin Halis, Sezer, Zafer, Ozdarendeli, Aykut, Unal, Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698857/
https://www.ncbi.nlm.nih.gov/pubmed/36366373
http://dx.doi.org/10.3390/vaccines10111865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698857/
https://www.ncbi.nlm.nih.gov/pubmed/36366373
http://dx.doi.org/10.3390/vaccines10111865

Ejemplares similares